Trials / Completed
CompletedNCT01420627
EZN-2279 in Patients With ADA-SCID
A Study of EZN-2279 (Polyethylene Glycol Recombinant Adenosine Deaminase [PEG-rADA]) Administered as a Weekly Intramuscular Injection in Patients With Adenosine Deaminase (ADA)-Deficient Combined Immunodeficiency
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Leadiant Biosciences, Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of EZN-2279 in patients with ADA-deficient combined immunodeficiency currently being treated with Adagen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | EZN-2279 | Weekly administration of EZN-2279 via IM injection |
| BIOLOGICAL | Adagen |
Timeline
- Start date
- 2014-01-24
- Primary completion
- 2018-04-10
- Completion
- 2019-05-29
- First posted
- 2011-08-19
- Last updated
- 2020-04-16
- Results posted
- 2020-04-16
Locations
6 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01420627. Inclusion in this directory is not an endorsement.